ST-segment elevation myocardial infarction (STEMI)

This session focuses on complex cases involving non-ST elevation myocardial infarction (NSTEMI), acute coronary syndromes (ACS), and challenging coronary anatomy. It presents unique clinical scenarios such as pediatric rescue PCI, management of significant distal lesions with proximal PCI, anatomical variations complicating interventions, mixed cardiovascular disease management,...

Focused on STEMI and acute thrombotic emergencies, this session presents a series of challenging cases involving heavy thrombus burden, acute total occlusions, and complex primary angioplasty scenarios. It explores innovative approaches beyond stenting, the role of drug-coated balloons in plaque erosion, and strategic decision-making in managing...

Thanks to the contribution of a team of interventional cardiologists from around the globe, get the international perspective on Late-breaking Clinical Trials and Science released at TCT 2025 - check out the list below.

A 51-year-old man with an inferior STEMI and multivessel disease was found to have a thrombotic sub-occlusion in the mid RCA. Angiography also revealed significant disease in the LAD. How would you manage this case?

Kalaivani Mahadevan and Fizzah Choudry provide their take on DAPT-SHOCK-MI presented by Zuzana Motovska at ESC Congress 2025 in Madrid.

In the overall population (n = 2,114), there was a significant interaction between the effect of randomisation to OCT guidance vs angiography guidance in lesions with moderate/severe calcification (n = 1,082) vs no/mild calcification (n = 1,032) on the 2-year rate of TVF (Pinteraction = 0.01).

Aaysha Cader provides her take on TACSI presented by Anders Jeppsson at ESC Congress 2025 in Madrid.

Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...

Mirvat Alasnag provides her take on OPTION-STEMI, presented by Youngkeun Ahn at ESC Congress 2025 in Madrid.

Ali Nazmi Calik interviews David Newby on the landmark DUAL-ACS trial results he presented at ESC Congress 2025 in Madrid.

The trial compared 3 months versus 12 months of dual antiplatelet therapy (DAPT) after myocardial infarction in an all-comer population. Findings suggest that shorter therapy may offer better...